In brief, the present study discovered that Btg2 is pathogenic in FSGS and mediates podocyte injury via EMT, which is enhanced by overexpressing Btg2 but inhibited by specifically deleting podocyte Btg2 gene. The gene discussed is BTG2; the disease is focal segmental glomerulosclerosis.